To include your compound in the COVID-19 Resource Center, submit it here.

Enterome's CD candidate well tolerated in Phase I

Enterome Bioscience S.A. (Paris, France) reported data from a Phase I trial in about 60

Read the full 152 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE